Alpine Woods Capital Investors’s Ligand Pharmaceuticals LGND Stock Holding History

Alpine Woods Capital Investors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,264	Closed	-$450K	–	422
2017 Q4	$450K	Hold	5,264	–	–	0.02%	319
2017 Q3	$447K	Hold	5,264	–	–	0.02%	324
2017 Q2	$399K	Hold	5,264	–	–	0.02%	334
2017 Q1	$348K	Hold	5,264	–	–	0.02%	356
2016 Q4	$334K	Hold	5,264	–	–	0.02%	359
2016 Q3	$335K	Buy	5,264 +1,710	+48%	+$126K	0.02%	358
2016 Q2	$264K	Sell	3,554 -724	-17%	-$53.7K	0.02%	366
2016 Q1	$286K	Sell	4,278 -571	-12%	-$34.7K	0.02%	357
2015 Q4	$328K	Hold	4,849	–	–	0.02%	364
2015 Q3	$259K	Sell	4,849 -1,465	-23%	-$88.9K	0.01%	418
2015 Q2	$397K	Sell	6,314 -2,685	-30%	-$146K	0.02%	347
2015 Q1	$433K	Sell	8,999 -1,834	-17%	-$70.3K	0.02%	340
2014 Q4	$360K	Sell	10,833 -10,876	-50%	-$354K	0.02%	356
2014 Q3	$636K	Buy	21,709 +4,889	+29%	+$162K	0.03%	299
2014 Q2	$654	Buy	+16,820	New	+$683K	0.02%	286

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Alpine Woods Capital Investors's LGND Position: Q1 2018 in Review

Alpine Woods Capital Investors sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 5,264 shares — an estimated $450K sold.

Alpine Woods Capital Investors first reported a position in LGND in Q2 2014 and held it in 15 quarters. The position peaked at $636K in Q3 2014. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

Alpine Woods Capital Investors reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Alpine Woods Capital Investors sold 5,264 Ligand Pharmaceuticals shares in Q1 2018, an estimated $450K.
Alpine Woods Capital Investors first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 15 quarters.
Alpine Woods Capital Investors's Ligand Pharmaceuticals position peaked at $636K in Q3 2014.
326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2018, filed 9 May 2018.